Filing Details

Accession Number:
0001209191-12-046331
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-09-20 17:43:01
Reporting Period:
2012-09-18
Filing Date:
2012-09-20
Accepted Time:
2012-09-20 17:43:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
831547 Spectrum Pharmaceuticals Inc SPPI Pharmaceutical Preparations (2834) 930979187
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1193918 Md C Rajesh Shrotriya 11500 S. Eastern Ave.
Suite 240
Henderson NV 89052
Chairman, Ceo & President Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2012-09-18 33,000 $13.02 2,365,934 No 4 S Direct
Common Stock Disposition 2012-09-19 33,000 $12.74 2,332,934 No 4 S Direct
Common Stock Disposition 2012-09-20 4,800 $12.50 2,328,134 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 11, 2012.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $13.15, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.53 to $13.37, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.